Seminar: New Modalities in Neurodegenerative Disease Management – Is Europe Ready to Innovate?
Early diagnosis of Alzheimer’s and Parkinson’s diseases remains a major challenge in Europe. Traditional diagnostic methods are often invasive, costly, and slow—delaying crucial interventions. However, groundbreaking innovations are on the horizon. The same is true for the treatment of these diseases.
New blood tests and AI-driven cognitive assessments are set to transform early detection, making it faster, more accessible, and less invasive. These advances could allow timely interventions, significantly improving patients’ quality of life. However, their implementation requires urgent attention from policymakers.
Is the European Union ready to integrate AI into healthcare? How do we ensure ethical AI use? How do we safeguard patient data? What legal frameworks are needed to support innovation while maintaining trust?
Join us for a high-level seminar where policymakers, industry experts, and academia will collaborate to explore how to bridge policy, technology, and healthcare for the future of neurogenerative disease diagnosis and care in Europe.
New blood tests and AI-driven cognitive assessments are set to transform early detection, making it faster, more accessible, and less invasive. These advances could allow timely interventions, significantly improving patients’ quality of life. However, their implementation requires urgent attention from policymakers.
Is the European Union ready to integrate AI into healthcare? How do we ensure ethical AI use? How do we safeguard patient data? What legal frameworks are needed to support innovation while maintaining trust?
Join us for a high-level seminar where policymakers, industry experts, and academia will collaborate to explore how to bridge policy, technology, and healthcare for the future of neurogenerative disease diagnosis and care in Europe.
Target: National contact points, Participants
Themes: Cluster 1 Health, Pillar 2
